В. П. Бондарев
Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical and Biological Agency · 138 works · 184 citations · h-index 6
Top works
- Genome-Editing and Biomedical Cell Products: Current State, Safety and Efficacy
- Current State of the Vaccine Prophylaxis of Particularly Dangerous Infections
- Стандарты качества иммунобиологических лекарственных препаратов - новое в Государственной фармакопее Российской Федерации
- Quality standards for immunobiological medicinal products - new texts in the State Pharmacopoeia of the Russian Federation
- Current problems with the standard samples of medicines in the Russian Federation
- Efficacy and Safety of Cholera Vaccines
- Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad
- Rotavirus Epidemiology and Vaccination Tactics
- General characteristics of adjuvants and their mechanisms of action (part 2)
- Epidemiological aspects of meningococcal infection and problems of vaccine prophylaxis
- The Use of a Heterologous Anti-Rabies Immunoglobulin for Specific Prevention of Human Rabies
- Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic
- [Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)].
- Therapeutic Efficacy of Triazavirin, a Novel Russian Chemotherapeutic, Against Influenza Virus A (H5N1)
- Characteristics of Phenotypic and Genetic Properties of Francisella tularensis 15 NIIEG Vaccine Strain with an Extended Storage Period
- Russian and foreign legislation on regulation of post approval variations in the dossier for the medicinal products
- Vaccine interchangeability: problems and prospects
- The Current Use of Biomedical Cell Products for Cancer Treatment
- Whole-Genome Sequencing and Phylogenetic Analysis of Francisella tularensis Vaccine Strain 15 NIIEG
- [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture].